Search Within

Gopakumar Vasudeva Iyer

Formats
  1. Meeting Abstract (202)
  2. Journal Article (118)
  3. Review (11)
  4. Book Section (5)
  5. Editorial (3)
  6. Correspondence (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (342)
  2. Genitourinary Oncology Service (342)
  3. Solid Tumor Oncology Division (342)
  4. Department of Pathology and Laboratory Medicine (214)
  5. GSK Faculty (194)
  6. Human Oncology and Pathogenesis Program (191)

More Groups

People
  1. Hikmat Al-Ahmadie (182)
  2. David Solit (181)
  3. Jonathan Rosenberg (169)
  4. Dean Bajorin (160)
  5. Bernard Bochner (129)
  6. Michael Berger (102)

More People

Years
  1. 2025 (14)
  2. 2024 (41)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (34)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (117)
  2. Laboratory Investigation (27)
  3. Modern Pathology (20)
  4. Cancer Research (17)
  5. Clinical Cancer Research (14)
  6. Annals of Oncology (13)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Nature Publishing Group (43)
  3. American Association for Cancer Research (34)
  4. Elsevier Inc. (33)
  5. Nature Research (20)
  6. Oxford University Press (15)

More Publishers

Results (342)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
    Meeting Abstract

    Deming, D. A.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.; Iyer, G.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database
    Meeting Abstract

    Deming, D. A.; Palma, N. A.; Navarro, W. H.; Iyer, G.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
    Meeting Abstract

    Powles, T.; Grande, E.; Van Der Heijden, M.; Necchi, A.; Iyer, G.; Drakaki, A.; Loriot, Y.; Sokolowski, K.; Zhang, W.; Galsky, M.
    European Urology (2024)

    Fulltext@MSK | Save
  • Molecular, immunohistochemical and clinical determinants of urothelial carcinoma of the bladder with nested subtype
    Meeting Abstract

    Koll, F. J.; Basar, M.; Chen, Z.; Tin, A. L.; Alam, S. M.; Tallman, J. E.; Clinton, T. N.; Whiting, K.; Chen, J. F.; Sarungbam, J.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Bedke, J.; Van Der Heijden, M. S.; Powles, T.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Vulsteke, C.; Swami, U.; Castellano, D.; Sarwar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Van Der Heijden, M. S.; Gupta, S.; Bedke, J.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Loriot, Y.; Dawson, N. A.; Hoffman-Censits, J. H.; Mar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save